Psoriasis Group Responds To 'Stunning' Results Of CNTO 1275 Clinical Trial
"The notion that a single, simple injection of this experimental treatment wipes psoriasis off a significant proportion of test subjects is a stunning development that will restore hope to even the most frustrated and cynical psoriasis patients among us," said Michael Paranzino, president of Psoriasis Cure Now. "There are many people who have had psoriasis for decades who have all but given up the thought that their skin might ever be clear again. Let's hope this treatment proves safe because it would seem to offer a powerful new treatment option if it can win FDA approval in coming years."
Last week, Psoriasis Cure Now reported that more than 70 potential treatments, including CNTO 1275, are in the research pipeline. That full list is available on the Psoriasis Cure Now website here: http://www.psoriasis-cure-now.org/hope.php. CNTO 1275 is a monoclonal antibody that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), which are believed to play a role in inflammatory diseases. Last July, Psoriasis Cure Now released a podcast that discussed anti-IL-12/23 treatments; that free podcast is available via iTunes or here: http://www.psoriasis-cure-now.org/podcasts.php. In the clinical trial, serious adverse events (requiring hospitalization) were observed in four percent of patients receiving CNTO 1275 compared with one percent of patients receiving placebo. CNTO 1275 is produced by Centocor, which also makes Remicade, approved for the treatment of psoriasis, psoriatic arthritis and other diseases. Centocor's press release reports that the company is moving forward to Phase Three testing of CNTO 1275.
Psoriasis Cure Now
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Backing, Christopher. "Psoriasis Group Responds To 'Stunning' Results Of CNTO 1275 Clinical Trial." Medical News Today. MediLexicon, Intl., 10 Feb. 2007. Web.
29 Apr. 2017. <http://www.medicalnewstoday.com/releases/62755.php>
Backing, C. (2007, February 10). "Psoriasis Group Responds To 'Stunning' Results Of CNTO 1275 Clinical Trial." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.